Indivior Pharmaceuticals (INDV) Other Operating Expenses (2024 - 2026)

Indivior Pharmaceuticals' Other Operating Expenses history runs 3 years deep, the most recent figure standing at -$1.0 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses changed 0.0% year-over-year to -$1.0 million in Q1 2026; TTM through Mar 2026 was -$3.0 million, a 98.47% increase from a year earlier, with the FY2025 full-year figure at -$3.0 million, up 98.46% from the prior year.
• Other Operating Expenses improved to -$1.0 million in Q1 2026 per INDV's latest filing, from -$2.0 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $1.0 million in Q4 2024 and bottomed at -$160.0 million in Q2 2024.
• The 3-year median for Other Operating Expenses is -$1.5 million (2025), against an average of -$33.2 million.
• Across the five-year window, Other Operating Expenses sank 300.0% in 2025 and changed 0.0% in 2026, its largest moves.
• Year by year, Other Operating Expenses stood at $1.0 million in 2024, then sank by 300.0% to -$2.0 million in 2025, then surged by 50.0% to -$1.0 million in 2026.
• Per Business Quant, the three latest INDV Other Operating Expenses figures stand at -$1.0 million (Q1 2026), -$2.0 million (Q4 2025), and -$1.0 million (Q1 2025).